Article Details

Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC - Urology Times

Retrieved on: 2024-02-22 21:08:48

Tags for this article:

Click the tags to see associated articles and topics

Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC - Urology Times. View article details on hiswai:

Excerpt

BioNTech and OncoC4 announce strategic collaboration to co-develop and commercialize novel checkpoint antibody in multiple solid tumor indications.

Article found on: www.urologytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up